Member Info for daveycaferacer

11 Apr 2016 Stifel Initiated Buy 11 Apr 2016 BofA/Merrill Initiated Buy 11 Apr 2016 Canaccord Genuity Initiated Buy

http://washingtonnewswire.com/2016-04-11-hutchison-china-meditech-limited-american-depositary-shares-hcm-coverage-initiated-at-canaccord-genuity/

Two new Analysts covering on the U.S. - should raise the profile a bit

No rush for me so looking forward to gauging the confidence of the Board and how they see things. I am also very interested in the pipeline, also NDA's for Savolitinib and Fruquintinib and if they achieve them when they expect to see first sales. Iam very impressed with the Company, their vision and execution but after 10 years of investment it will be interesting to see how confident they are about realizing that investment.

I will be the person asking a number of questions about the IPO performance and the fact it had to be discounted, intention to remain listed on AIM in the long term and a few others o;-)

btw, I'm going to the AGM, let me know if anyone else will be attending

I feel very inferior with my £100K but if I hadn't have been such a complete idiot and sold at £3.50 a few years ago I'd be sitting on a very large holding Having said that I have a 10-15 year investment timescale when I'm expecting HCM to have a $20bn market cap, if everything comes together, the pipeline materializes and we get the launches we expect

I think once the excess ADR allocations have been taken up we will start to move up significantly and as you say miti, we have drug trial announcements due on many fronts. We also have big property compensation due at the JV level. The rest of this year will provide ongoing positive news updates and we could in fact get new drug applications submitted for Savolitinib and Fruquintinib.

Today we have finally got back to the issue price of $13.50 Let's hope American Investors realize what a bargain this is and we continue to rise based on the brilliant FY15 results and the fact we have one or possibly two first in class drugs being submitted for approval later in the year, each with forecast peak annual sales in excess of $1bn

IPO Volume 1Q 2015 2Q 2015 3Q 2015 4Q 2015 1Q 2016 Proceeds Raised (US$)$5.5b $12.7b $5.1b $6.8b $0.7b Shows the Bottom fell out of the IPO market in Q1

HCM in London DOWN 9% since NASDAQ IPO HCM on NASDAQ down 1.3% since NASDAQ IPO as a result of currency rates and the fact we heavily discounted the IPO instead of pulling it In the long run I hope the Company will be proved right in their call to go ahead with the IPO in order to accelerate the drugs pipeline and push towards launch for some candidates. Time will tell but currently I think they have probably made the right call...just, but I will be asking the Board at the AGM to comment on it.

Great point about the free float Matt, I hadn't thought too much about that or indeed the exchange rate. Disappointing that the value of the much larger pool of shares is being driven by the much smaller pool. I will be asking the Board at the AGM for feedback on the NASDAQ listing and whether they are disappointed in having to reduce the value of the ADR's and also how they seem the long term prospects, in the context of a possible complete de-list off AIM....

This is a very long term play and I think too many Investors, particularly Private ones, are not interested in investing in a Company for years or decades. I think the true value of HCM is yet to be realized.

Not me, like the Directors I only ever buy because like them, I know what a fantastic Company this is and what it will become in a decade (another $20bn market cap Pharmacyclics equivalent)

Agreed Matt, my only problem is if you look at the progress in the last year and how close we are to two drugs going into approval I'd expect an even higher market cap. I mean, we could have revs in the next 2-3 years of $2-3bn based on the rNPV assessment Edison did a year ago, with an associated massive uplift in EPS and Profit. I continue to buy regularly at these prices like the Directors.

Not to everyone's taste but I think the Company needs to start pushing up its profile and get some research notes out It is over a year since the last Edison paper, which is woefully out of date now, an example being the fact they forecast $157m revs in 2015, and we delivered $178m, all other metrics were exceeded too.

Thankyou very much miti Interesting that Christian admits to frustrations with AIM, lack of liquidity and lack of Analyst coverage. I can see a day where the Company de-lists from AIM altogether and only maintains a NASDAQ listing, or possibly runs a NASDAQ and Hang Seng dual listing. The reasons for an AIM listing seem to have gone away to me, we have outgrown it, and no longer need to raise capital in London. I am still convinced our market cap will be many many multiples of today's in the next 5 - 10 years. It will be good to see some U.S. Institutional Investors taking up long term positions in the Company going forward. I'd also like to see some independent and commissioned research notes.

I seem to have gone over the limit of my free subscription to FT would you mind posting the article or an extract of it if possible please miti?

" Christian Hogg, Executive Director and Chief Executive Officer, has purchased 36,600 American Depositary Shares ("ADSs", each representing one-half of one ordinary share) of the Company at a price of US$13.5 per ADS on March 25, 2016. " Mr Hogg and his fellow Directors know the true value of our Company and the fact we will have a market cap of tend of billions of dollars within the next 5-10 years. The recent growth will pale into insignificance when our first drug candidates are approved and the market can finally see revenue and profit will be many multiples of today's numbers IMO Great to see Mr Hogg and Ms Shah buying in the American market - hopefully that will give a signal to that market about where they see the future. Not insignificant purchases either.....

I see some people in the U.S. are saying avoid HCM for 2 reasons 1. because it is in an out of favour sector and 2. it is Chinese They are probably 2 reasons to invest IMO And compared to Beigene our pipeline looks stunning with possible NDA's at the end of the year and launches in 2017, we could have revenues measured in $billions within two or three years